FDA approves Viatris' low-dose estrogen weekly patch?

6.5 pt (24h)Health & MedicineWeekly2g

PolymarketVerifica disponibilitàSenza KYC2% di commissioneDati di risoluzione verificatiDiscretamente calibrato

Probabilità implicita attuale

Sì 65.3%-0.1pt

Qualita del mercato

32 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

101,5 €

Bassa liquidità

Bid / Ask

44.0% / 87.0%

Spread

43.0 pt

Spread ampio

Variazione 7g

+9.5 pts

Dati di mercato

Aggiornato 8 minuti fa

1 lug 26, 6:1430 lug 26, 17:59

Trend

Esito24hProbabilità

Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria

Esito scelto

Yes66%

Puntata (USDT)

Regole

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Trend del volume

2 lug20g di dati21 lug

Mercati Correlati

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$19B: 4%

POLYMARKET

Chipotle chicken burrito price in July 2026

15,5K €

At least $9.75: 99%

KALSHI

What price will Bitcoin hit July 27-August 2?

14,6K €

↓ 62,000: 64%

POLYMARKET

Price of NVIDIA B200 compute by Jul 31, 2026?

4,4K €

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

4,1K €

Above $2.71: 50%

KALSHI

What price will Ethereum hit July 27-August 2?

2,3K €

↓ 1,900: 100%

POLYMARKET

Attivi in questi argomenti

EthereumETH$1,879.49-3.41%

BitcoinBTC$63,334.21-3.03%

SolanaSOL$73.32-4.06%

XRPXRP$1.06-4.30%

BNBBNB$566.58-1.11%

DogecoinDOGE$0.0701-3.66%

Notizie Correlate

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regole

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

FDA approves Viatris' low-dose estrogen weekly patch?

6.5 pt (24h)Health & MedicineWeekly2g

PolymarketVerifica disponibilitàSenza KYC2% di commissioneDati di risoluzione verificatiDiscretamente calibrato

Probabilità implicita attuale

Sì 65.3%-0.1pt

Qualita del mercato

32 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

101,5 €

Bassa liquidità

Bid / Ask

44.0% / 87.0%

Spread

43.0 pt

Spread ampio

Variazione 7g

+9.5 pts

Dati di mercato

Aggiornato 8 minuti fa

1 lug 26, 6:1430 lug 26, 17:59

Trend

Esito24hProbabilità

Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria

Esito scelto

Yes66%

Puntata (USDT)

Regole

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Trend del volume

2 lug20g di dati21 lug

Mercati Correlati

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$19B: 4%

POLYMARKET

Chipotle chicken burrito price in July 2026

15,5K €

At least $9.75: 99%

KALSHI

What price will Bitcoin hit July 27-August 2?

14,6K €

↓ 62,000: 64%

POLYMARKET

Price of NVIDIA B200 compute by Jul 31, 2026?

4,4K €

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

4,1K €

Above $2.71: 50%

KALSHI

What price will Ethereum hit July 27-August 2?

2,3K €

↓ 1,900: 100%

POLYMARKET

Attivi in questi argomenti

EthereumETH$1,879.49-3.41%

BitcoinBTC$63,334.21-3.03%

SolanaSOL$73.32-4.06%

XRPXRP$1.06-4.30%

BNBBNB$566.58-1.11%

DogecoinDOGE$0.0701-3.66%

Notizie Correlate

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regole

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs